open access

Vol 10, No 2 (2007)
Clinical nuclear medicine
Published online: 2007-05-23
Submitted: 2012-01-23
Get Citation

Clinical significance of metabolic superscan in patients with hyperthyroidism

Magdy H. Kotb, Tarek El-Maghraby, Khaled Khalafallah, Walid Omar, Bahaa Demian Grace, Adil AL-Nahhas
Nucl. Med. Rev 2007;10(2):76-81.

open access

Vol 10, No 2 (2007)
Clinical nuclear medicine
Published online: 2007-05-23
Submitted: 2012-01-23

Abstract

BACKGROUND: Hyperthyroid patients commonly complain of generalized bony aches, which are frequently overlooked due to the more prominent symptoms of cardiovascular and nervous disturbances. Hyperthyroid patients are expected to have abnormal bone metabolism as part of the generalized hypermetabolic status. The aim of this study is to verify the presence of metabolic bone superscan in association with the hypermetabolic stats in various groups of hyperthyroidism. Secondly, to correlate these superscan features with the various laboratory results in hyperthyroid patients.
MATERIAL AND METHODS: Forty-five hyperthyroid patients confirmed by clinical and laboratory results were enrolled in this work. In all patients, a 99mTc-pertechnetate thyroid uptake scan was acquired. On a different day, total body bone scan was acquired three hours post IV injection of 555-925 MBq of 99mTc-MDP. Serum FT3, FT4, TSH, Ca++, alkaline phosphatase (AP) and parathyroid hormone (PTH) were monitored in all patients as markers of thyroid and bone metabolism. Ten cases with no thyroid diseases were included as a control group. Patients with thyroiditis or long history of antithyroid drugs for more than one year were excluded from the study.
RESULTS: The patients were subdivided into three groups: Graves´ disease (GD) (n = 30), toxic nodular goiter (TNG) (n = 10) and autonomous toxic adenoma (AT) (n = 5). The TSH for the whole group was significantly suppressed compared to the control group with higher suppression in the Graves´ disease group than in the TNG or AT groups. 99mTc-pertechnetate uptake values in the Graves´ disease group were significantly higher than the TNG and AT groups (p < 0.05). Metabolic superscan (MSS) was noted in 90% of the Graves´ cases, 20% in TNG and in none of the AT group. There were no significant differences regarding Ca+, AP and PTH between the Graves´ and non-Graves´ groups (p > 0.05).
CONCLUSIONS: Disturbances in bone metabolism are more prevalent in Graves´ disease than in other types of hyperthyroidism. The addition of the bone scan to the diagnostic work up of patients with Graves´ disease is a sensitive indicator for metabolic bone changes and could help in the future management and follow up for this group of patients.

Abstract

BACKGROUND: Hyperthyroid patients commonly complain of generalized bony aches, which are frequently overlooked due to the more prominent symptoms of cardiovascular and nervous disturbances. Hyperthyroid patients are expected to have abnormal bone metabolism as part of the generalized hypermetabolic status. The aim of this study is to verify the presence of metabolic bone superscan in association with the hypermetabolic stats in various groups of hyperthyroidism. Secondly, to correlate these superscan features with the various laboratory results in hyperthyroid patients.
MATERIAL AND METHODS: Forty-five hyperthyroid patients confirmed by clinical and laboratory results were enrolled in this work. In all patients, a 99mTc-pertechnetate thyroid uptake scan was acquired. On a different day, total body bone scan was acquired three hours post IV injection of 555-925 MBq of 99mTc-MDP. Serum FT3, FT4, TSH, Ca++, alkaline phosphatase (AP) and parathyroid hormone (PTH) were monitored in all patients as markers of thyroid and bone metabolism. Ten cases with no thyroid diseases were included as a control group. Patients with thyroiditis or long history of antithyroid drugs for more than one year were excluded from the study.
RESULTS: The patients were subdivided into three groups: Graves´ disease (GD) (n = 30), toxic nodular goiter (TNG) (n = 10) and autonomous toxic adenoma (AT) (n = 5). The TSH for the whole group was significantly suppressed compared to the control group with higher suppression in the Graves´ disease group than in the TNG or AT groups. 99mTc-pertechnetate uptake values in the Graves´ disease group were significantly higher than the TNG and AT groups (p < 0.05). Metabolic superscan (MSS) was noted in 90% of the Graves´ cases, 20% in TNG and in none of the AT group. There were no significant differences regarding Ca+, AP and PTH between the Graves´ and non-Graves´ groups (p > 0.05).
CONCLUSIONS: Disturbances in bone metabolism are more prevalent in Graves´ disease than in other types of hyperthyroidism. The addition of the bone scan to the diagnostic work up of patients with Graves´ disease is a sensitive indicator for metabolic bone changes and could help in the future management and follow up for this group of patients.
Get Citation

Keywords

hyperthyroidism; Graves’ disease; superscan; bone scan; metabolic bone changes

About this article
Title

Clinical significance of metabolic superscan in patients with hyperthyroidism

Journal

Nuclear Medicine Review

Issue

Vol 10, No 2 (2007)

Pages

76-81

Published online

2007-05-23

Bibliographic record

Nucl. Med. Rev 2007;10(2):76-81.

Keywords

hyperthyroidism
Graves’ disease
superscan
bone scan
metabolic bone changes

Authors

Magdy H. Kotb
Tarek El-Maghraby
Khaled Khalafallah
Walid Omar
Bahaa Demian Grace
Adil AL-Nahhas

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl